Navigation Links
Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
Date:10/23/2008

-Sapirstein to Present Company Overview-

PRINCETON, N.J. and SAN DIEGO, Oct. 23 /PRNewswire/ -- Tobira Therapeutics, Inc., a company focused on the development of medicines with novel mechanisms of actions for infectious diseases, today announced it will present a corporate overview at the 2008 BIO Investor Forum. James Sapirstein, Chief Executive Officer and President will summarize the current status of the company including the status of TBR-652, a CCR5 antagonist in development for HIV-1 infection in adults. The presentation is scheduled for October 30, 2008 at 9:00 AM PST at The Palace Hotel, Two New Montgomery Street, San Francisco, Calif.

"We are delighted to share the growth Tobira Therapeutics, Inc. has experienced in the last 18 months at the BIO Investor Forum," said James Sapirstein. "This is a unique opportunity to review the great potential that we have to offer." Tobira Therapeutics is a clinical stage company and is not developing new technologies. The company is expanding its pipeline by being the partner of choice for suppliers, researchers, and alliance partners. A key component of Tobira's strategy is to acquire global rights to additional product candidates in infectious diseases, while continuing to develop and commercialize new products and line extensions.

The BIO Investor Forum will feature more than 190 public and venture-stage company presentations, in addition to drug and technology therapeutic workshops, breakout sessions, one-on-one investor meetings, and networking with industry executives and investors.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

Contact:

Tobira Therapeutics Inc.

Antoinette Bobbitt, Senior Director, Corporate and Business Development

abobbitt@tobiratherapeutics.com Tel: +1 609-897-1102

http://www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
3. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
4. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. Ltd. ... KRW (US $18.9M) Series A financing. This financing round ... Tech Venture and SNU Bio Angel. This new funding ... billion KRW (US $27.7M) since its founding in 2015. ... bolster the development and commercialization of its immuno-oncology programs, ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
Breaking Biology News(10 mins):